91ֱ��

All publications

Journal articles

• Davis S, Goodacre S, Horner D, Pandor A, Holland M, de Wit K, Hunt BJ & Griffin XL (2024) . BMJ Medicine, 3(1), e000408-e000408.
• Khalid TY, Peters TJ, Pocock LV, Drew S, Hardcastle SA, Paskins Z, Davis S, Kariki EP & Clark EM (2024) . Archives of Osteoporosis, 19(1).
• Davis S, Pandor A, Sampson F, Hamilton J, Nelson-Piercy C, Hunt BJ, Daru J & Goodacre S (2024) . Journal of Thrombosis and Haemostasis.
• Hunt B, Sampson F, Goodacre S, Pandor A, Nelson-Piercy C, Daru J, Carser R, Metry A & Davis S (2023) . Research and Practice in Thrombosis and Haemostasis, 7, 101939-101939.
• Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi‐Bee J & Sahota O (2022) . JBMR Plus.
• Khera T, Hunt LP, Davis S, Gooberman-Hill R, Thom H, Xu Y, Paskins Z, Peters TJ, Tobias JH & Clark EM (2022) . Age and Ageing, 51(3).
• Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J & Sahota O (2022) . Osteoporosis International.
• Mattia L, Davis S, Mark-Wagstaff C, Abrahamsen B, Peel N, Eastell R & Schini M (2022) . Bone, 158.
• Horner D, Goodacre S, Davis S, Burton N & Hunt BJ (2021) . BMJ, 373, n1106.
• Clark E, Davis S, Gooberman-Hill R, Hunt L, Khera T, Zoe P, Tim P & Jon T (2021) . Bone Reports, 14, 100958.
• (2021) World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2021): Poster Abstracts. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 32(Suppl 1), 119-410.
• Leaviss J, Davis S, Ren S, Hamilton J, Scope A, Booth A, Sutton A, Parry G, Buszewicz M, Moss-Morris R & White P (2020) . Health Technology Assessment, 24(46).
• Davis S, Simpson E, Hamilton J, James MM-S, Rawdin A, Wong R, Goka E, Gittoes N & Selby P (2020) . Health Technology Assessment, 24(29), 1-314.
• Simpson E, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P & Davis S (2020) . Bone, 130.
• Pandor A, Horner D, Davis S, Goodacre S, Stevens JW, Clowes M, Hunt BJ, Nokes T, Keenan J & de Wit K (2019) . Health Technology Assessment, 23(63), 1-190.
• Khera TK, Burston A, Davis S, Drew S, Gooberman-Hill R, Paskins Z, Peters TJ, Tobias JH & Clark EM (2019) . Archives of Osteoporosis, 14(1).
• Horner D, Goodacre S, Pandor A, Nokes T, Keenan J, Hunt B, Davis S, Stevens JW & Hogg K (2019) . Emergency Medicine Journal, 0, 1-6.
• Davis S, Goodacre S, Pandor A, Horner D, Stevens JW, Wit K & Hunt BJ (2019) . British Journal of Haematology, 186(1), 166-168.
• Davis S, Rafia R, Carroll C, Hamilton J & Essat M (2018) . Pharmacoeconomics.
• Julious SA, Horspool MJ, Davis S, Franklin M, Smithson WH, Norman P, Simpson RM, Elphick H, Bortolami O & Cooper C (2018) . BMJ Open, 8(4).
• Rafia R, Pandor A, Davis S, Stevens JW, Harnan S, Clowes M, Sorour Y & Cutting R (2018) . PharmacoEconomics, 36(10), 1143-1151.
• van Baal P, Morton A, Brouwer W, Meltzer D & Davis S (2017) . BMJ, 359.
• Möller J, Davis S, Stevenson M & Caro JJ (2017) . PharmacoEconomics, 35(10), 1103-1109.
• Franklin M, Davis S, Horspool M, Kua WS & Julious S (2017) . PharmacoEconomics, 35(5), 561-573.
• Julious SA, Horspool MJ, Davis S, Bradburn M, Norman P, Shephard N, Cooper CL, Smithson WH, Boote J, Elphick H , Loban A et al (2016) . Health Technology Assessment, 20(93), 1-154.
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al (2016) . Health Technology Assessment, 20(78), 1-406.
• Sanderson J, Martyn-St James M, Stevens J, Goka E, Wong R, Campbell F, Selby P, Gittoes N & Davis S (2016) . Bone, 89, 52-58.
• Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P & Wong R (2015) . PharmacoEconomics, 33(11), 1187-1194.
• Holmes M, Davis S & Simpson E (2015) . PharmacoEconomics, 33(3), 225-233.
• Pennington B & Davis S (2014) . Value in Health, 17(8), 762-771.
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M & Taylor RS (2014) . International Journal of Technology Assessment in Health Care, 30(3), 312-324.
• Akunne A, Davis S, Westby M & Young J (2014) . Eur J Orthop Surg Traumatol, 24(2), 187-195.
• (2014) . Heart, 100(4), 350-350.
• Horspool MJ, Julious SA, Boote J, Bradburn MJ, Cooper CL, Davis S, Elphick H, Norman P, Smithson WH & vanStaa T (2013) . Trials, 14(1).
• Tosh J, Archer R, Davis S, Stevenson M & Stevens JW (2013) . Pharmacoeconomics, 31(8), 653-661.
• Davis S & Wailoo A (2013) . Health Qual Life Outcomes, 11, 20.
• Petkar S, Bullock I, Davis S & Cooper P (2013) . Heart.
• Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P & Moxham T (2013) . Age Ageing, 42(1), 14-20.
• Davis S, Westby M, Petkar S & Pitcher D (2013) . Heart, 99(11), 805-810.
• Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A , Jeffreys M et al (2012) . Health Technol Assess, 16(21), 1-470.
• Davis S, Westby M, Pitcher D & Petkar S (2012) . Europace, 14(3), 402-409.
• Westby M, Bullock I, Cooper PN, Davis S & Guideline Dev Grp (2010) . BRIT MED J, 341.
• Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S , Chisholm I et al (2008) . Health Technol Assess, 12(27), iii-124.
• Bansback N, Davis S & Brazier J (2007) . Eye (Lond), 21(12), 1455-1463.
• Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
• Stevenson M, Davis S, Lloyd-Jones M & Beverley C (2007) . Health Technol Assess, 11(4), 1-134.
• Ward S, Simpson E, Davis S, Hind D, Rees A & Wilkinson A (2007) . Health Technol Assess, 11(40), 1-144.
• Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) . Health Technol Assess, 11(7), iii-231.
• Brennan A, Akehurst R, Davis S, Sakai H & Abbott V (2007) . Value Health, 10(1), 32-41.
• Stevenson M, Davis S & Kanis J (2006) . Women's Health Medicine, 3(4), 149-151.
• Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S & Oakley J (2005) . Health Technol Assess, 9(22), 1-160.
• Horner DE, Davis S, Pandor A, Shulver H, Goodacre S, Hind D, Rex S, Gillett M, Bursnall M, Griffin X , Holland M et al () . Health Technology Assessment, 1-166.
• Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T, Gittoes N, Davis S, Baily A, Holmes M & Leonardi-Bee J () . Health Technology Assessment, 1-169.
• Guthrie B, Rogers G, Livingstone S, Morales DR, Donnan P, Davis S, Youn JH, Hainsworth R, Thompson A & Payne K () . Health and Social Care Delivery Research, 1-275.
• Paskins Z, Moult A, Corp N, Bastounis A, Davis S, Narayanasamy MJ, Griffin J, Gittoes N, Leonardi-Bee J, Langley T , Bishop S et al () . Osteoporosis International.
• Davis S, Goodacre S, Horner D, Pandor A, Griffin X, de Wit K, Hunt B & Holland M () Decision-analysis modelling of effectiveness and cost-effectiveness of pharmacological thromboprophylaxis for surgical inpatients, using variable risk assessment models or other strategies. Journal of Thrombosis and Haemostasis.
• Davis S, Pandor A, Sampson F, Hamilton J, Nelson-Piercy C, Beverley H, Jahnavi D, Goodacre S, Carser R, Rooney G & Clowes M () Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research. Health Technology Assessment.
• Davis S () Risk assessment models for venous thromboembolism in pregnancy and in the puerperium: a systematic review. BMJ Open.
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al () . Health Technology Assessment, 20(78), 407-424.
• Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye N, Tappenden P & Kaltenthaler E () . Health Technology Assessment, 19(60), 1-110.

Chapters

• Davis S, King B & Raine JM (2006) (pp. 199-215). Wiley
• Parkinson J, Davis S & Staa TV (2006) (pp. 341-348). Wiley

Conference proceedings papers

• Paskins Z, Moult A, Corp N, Bastounis A, Davis S, Narayanasamy MJ, Griffin J, Gittoes N, Leonardi-Bee J, Langley T , Bishop S et al (2023) RESEARCH PRIORITIES REGARDING THE USE OF BISPHOSPHONATES FOR OSTEOPOROSIS: A UK PRIORITY SETTING EXERCISE. RHEUMATOLOGY, Vol. 62
• Davis S, Pandor A, Sampson F, Nelson-Piercy C, Hunt B & Daru J (2023) Thromboprophylaxis during pregnancy and the puerperium: A systematic review, qualitative study and economic evaluation to estimate the value and acceptability of future research. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol. 130 (pp 20-20)
• Mattia L, Mark-Wagstaff C, Abrahamsen B, Davis S, Peel N, Eastell R & Schini M (2022) Monitoring Bisphosphonate Treatment In Primary Care: PINP And Osteoporosis In 91ֱ�� Evaluation (POSE Study). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 64-65)
• Clark E, Khera T, Hunt L, Gooberman-Hill R, Paskins Z, Peters T, Tobias J & Davis S (2022) Addition of symptoms to traditional risk factors improves prediction of those at high risk of vertebral fractures: Results of the Vfrac study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 60-60)
• Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J & Sahota O (2021) ASSESSING THE EFFECTIVENESS OF BISPHOSPHONATES FOR THE PREVENTION OF FRAGILITY FRACTURES: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S270-S270)
• Mattia L, Mark-Wagstaff C, Abrahamsen B, Davis S, Peel N, Eastell R & Schini M (2021) MONITORING BISPHOSPHONATE TREATMENT IN PRIMARY CARE: PINP AND OSTEOPOROSIS IN SHEFFIELD EVALUATION (POSE STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S288-S288)
• Elphick H, Horspool M, Davis S, Bradburn M, Norman P, Shephard N, Cooper C, Smithson WH, Boote J, Loban A , Franklin M et al (2016) . 1.6 General Practice and Primary Care
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
• Brennan A, Wilson R, Davis S, Brandtmuller A & Akehurst R (2007) Economic evaluation of the use of lanthanum carbonate from an Australian perspective. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 22 (pp 186-186)
• Brennan A, Akehurst R, Davis S & Sakai H (2004) Lanthanum carbonate for the treatment of hyperphosphataemia: Development of a cost effectiveness model. VALUE HEALTH, Vol. 7(6) (pp 805-805)

Reports

• Kua WS & Davis S (2016)

Preprints

• Sampson FC, Davis S, Kuczawski M, Carser R, Hunt BJ, Goodacre S, Pandor A, Nelson-Piercy C & Daru J (2024) , Research Square Platform LLC.